When the Wrong Label Leads to the Wrong Pills: What Happens When ADHD Finally Gets Diagnosed
Tuesday, August 19, 2025.
For years, adults stumbling through life with distraction, restlessness, and unfinished projects have been told they were “just anxious” or “probably depressed.”
Doctors handed over antidepressants like they were aspirin, hoping to quiet the storm.
The pills dulled the edges but never fixed the engine.
Because the problem wasn’t depression. It was ADHD—misunderstood, underdiagnosed, and misfiled into the wrong drawer.
A new Finnish study shows what happens when the right label finally lands.
Once adults are treated for ADHD, their antidepressant use drops. In other words: call the thing by its real name, and the shelves of orange pill bottles begin to thin out.
Finland: Land of Reindeer and Relentless Data
Finland has an unfair advantage in studies like this: it tracks everything. Prescriptions, diagnoses, reimbursements—the whole record, cradle to grave.
Researchers dug into those registries for a study published in Acta Psychiatrica Scandinavica. They followed adults newly diagnosed with ADHD between 2015 and 2020, comparing them with matched controls who never carried the label.
Then they asked a simple question: what happens to antidepressant use once ADHD treatment begins?
And the Answer Is… They Go Down
In adults with ADHD, antidepressant use dropped. In controls, nothing changed.
Translation: many adults being treated for depression or anxiety were actually living with undiagnosed ADHD. Once their attention system was treated directly, the antidepressants became less necessary.
This echoes what I explored in ADHD’s unexpected impacts: the condition doesn’t just create distraction, it reshapes health, mood, and daily life in ways we rarely name. Now we can add medication history to the list of places where ADHD leaves its fingerprints.
The Children’s Trail of Prescriptions
Kids with ADHD showed their own strange pattern. Before diagnosis, they were more likely than their peers to be prescribed antibiotics, anti-inflammatories, even asthma medications. After ADHD treatment began, those numbers dropped more steeply.
The body calmed once the brain was recognized. Fewer flares, fewer sick visits, fewer side trips to the pharmacy.
Sticking With Treatment
Nearly 95% of patients filled their first ADHD prescription, and 80% did so within ten days. High by any psychiatric measure.
But persistence was another story. Younger kids stayed on medication the longest—parents kept them steady. Adults did reasonably well. Teenagers, though, dropped off fast. Fewer than half were still taking ADHD meds a year later. It’s almost a cliché: teenagers don’t like being told what pills to take.
The American Contrast: Overdiagnosed Kids, Underdiagnosed Adults
In the United States, ADHD lives with a split reputation.
On one hand, the culture frets about overdiagnosed children—especially boys who can’t sit still in class.
On the other, millions of adults with ADHD go undiagnosed. Untreated ADHD is among the hidden stressors in American marriages.
Research suggests fewer than 1 in 5 adults with ADHD in the U.S. ever receive a proper diagnosis. Which means countless people are treated for the wrong thing, their medicine cabinets lined with SSRIs, sleep aids, reflux drugs, and antipsychotics.
In other words, close to 90% of adult American ADHD remains undiagnosed and untreated.
Finland Sees What America Can’t
Why does Finland see the pattern so clearly? Because it has a single, unified health system. Every prescription, every diagnosis, every follow-up lives in the same national record.
America, by contrast, runs on fragmentation.
Insurance changes, doctors’ offices don’t share charts, pharmacies don’t talk to each other. A person could spend fifteen years on antidepressants for undiagnosed ADHD, bouncing from clinic to clinic, and nobody would ever see the through-line.
So Finland gets to say, “Look, antidepressant use drops when ADHD is treated.” America just sees noise.
Why It Matters
This isn’t just about pills. It’s about the cost of mislabeling.
Untreated ADHD doesn’t just create suffering—it creates clutter: years of wrong medications, false starts, and diagnoses that never quite fit. Getting the diagnosis right clears the junk drawer. It simplifies. It spares people the wear and tear of being told they are something they’re not.
The Cultural Message
Registry studies can’t prove causation, but the pattern here is hard to ignore. It tells us something unflattering: for decades, we’ve medicated the mislabel.
The irony is almost too neat: Finland’s health system can show us truth at scale because it looks at the whole person over time.
America’s system produces only fragmentary data, and fragments are easy to misinterpret.
The Takeaway
Getting ADHD right isn’t just about better focus or calmer evenings. It’s about cleaning up years of diagnostic noise, cutting back unnecessary medications, and giving people the right name for their struggle.
Because the wrong label doesn’t just waste pills. It can also waste years.
Be Well, Stay Kind, and Godspeed.
REFERENCES:
Westman, E., Prami, T., Kallio, A., Iso-Mustajärvi, I., Jukka, J., Raittinen, P., Korhonen, M. J., Puustjärvi, A., & Leppämäki, S. (2025). Use of antidepressants decreased after initiation of ADHD treatment in adults—A Finnish nationwide register study describing use of ADHD and non-ADHD medication in people with and without ADHD.Acta Psychiatrica Scandinavica, 152(2), 97–110. https://doi.org/10.1111/acps.13785
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., ... & Zaslavsky, A. M. (2006). The prevalence and correlates of adult ADHD in the United States. American Journal of Psychiatry, 163(4), 716–723. https://doi.org/10.1176/ajp.2006.163.4.716
Faraone, S. V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M. A., ... & Wang, Y. (2021). The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neuroscience & Biobehavioral Reviews, 128, 789–818. https://doi.org/10.1016/j.neubiorev.2021.01.022
Kooij, J. J. S., Bijlenga, D., Salerno, L., Jaeschke, R., Bitter, I., Balázs, J., ... & Asherson, P. (2019). Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European Psychiatry, 56, 14–34. https://doi.org/10.1016/j.eurpsy.2018.11.001
Katzman, M. A., Bilkey, T. S., Chokka, P. R., Fallu, A., & Klassen, L. J. (2017). Adult ADHD and comorbid disorders: Clinical implications of a dimensional approach. BMC Psychiatry, 17(1), 302. https://doi.org/10.1186/s12888-017-1463-3